The Food and Drug Administration has approved a new drug from Merck designed to protect infants from respiratory syncytial ...

By Chad Terhune and Dan Levine (Reuters) -One of the new vaccine advisers picked by U.S. Health Secretary Robert F. Kennedy ...

THURSDAY, June 12, 2025 (HealthDay News) — A newly approved shot could soon help protect babies from respiratory syncytial ...

BioNTech has agreed to buy another specialist in mRNA-based vaccines and therapeutics, fellow German biotech CureVac, in an all-stock deal valued at around $1.25 billion.

Merck KGaA has shed more light on the failure of its lupus drug in one cohort of patients, while pointing to secondary ...

The FDA has approved Enflonsia (clesrovimab-cfor) for the prevention of RSV lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season.

Cohort B of the Phase 2 study indicates all doses of enpatoran were associated with higher BICLA response rates compared with placebo, though the ...

Merck shares fell 1.27%, lagging behind the S&P 500’s smaller dip of 0.27%. This decline comes despite Merck’s prior ...

Seven of those fired had received up to US$55,000 from drugmakers. Read more at straitstimes.com. Read more at ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of the MOBILIZE-1 ...